Drug-releasing vaginal rings for HIV/STI and pregnancy prevention: a review of recent advances and clinical applications

References

• Celum CL, Delany-Moretlwe S, McConnell M, et al. Rethinking HIV prevention to prepare for oral PrEP implementation for young African women. J Int AIDS Soc. 2015;18(4 Suppl 3):20227.
   PubMed Web of Science ®Google Scholar
• Baeten J, Celum C. Oral antiretroviral chemoprophylaxis: current status. Curr Opin HIV AIDS. 2012;7(6):514–519.
   PubMed Web of Science ®Google Scholar
• Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. New Engl J Med. 2012;367(5):399–410.
   PubMed Web of Science ®Google Scholar
• Baeten JM, Palanee-Phillips T, Brown ER, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375(22):2121–2132.
   PubMed Web of Science ®Google Scholar
• Nel A, van Niekerk N, Kapiga S, et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. New Engl J Med. 2016;375(22):2133–2143.
   PubMed Web of Science ®Google Scholar
• Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–422.
   PubMed Web of Science ®Google Scholar
• Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015 Feb 5;372(6):509–518.
   PubMed Web of Science ®Google Scholar
• Landovitz R. HPTN083 Interim results: preexposure prophylaxis (PrEP) containing long-acting injectable cabotegravir (CAB-LA) is safe and highly effective for cisgender men and transgender women who have sex with men (MSM, TGW). 23rd International AIDS Conference (virtual).
   Google Scholar
• Fernández-Romero JA, Deal C, Herold BC, et al. Multipurpose prevention technologies: the future of HIV and STI protection. Trends Microbiol. 2015;23(7):429–436.
   PubMed Web of Science ®Google Scholar
• Malcolm RK, Boyd P, McCoy CF, et al. Beyond HIV microbicides: multipurpose prevention technology products. BJOG. 2014;121(Suppl 5):62–69.
   PubMed Web of Science ®Google Scholar
• Thurman AR, Clark MR, Hurlburt JA, et al. Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies. Int J Womens Health. 2013 Oct 21;5:695–708.
   PubMedGoogle Scholar
• Kiser PF, Johnson TJ, Clark JT. State of the art in intravaginal ring technology for topical prophylaxis of HIV infection. AIDS Rev. 2012 Jan-Mar;14(1):62–77.
   PubMed Web of Science ®Google Scholar
• Friend DR. An update on multipurpose prevention technologies for the prevention of HIV transmission and pregnancy. Expert Opin Drug Deliv. 2016;13(4):533–545.
   PubMed Web of Science ®Google Scholar
• Malcolm RK, Edwards KL, Kiser P, et al. Advances in microbicide vaginal rings. Antiviral Res. 2010 Dec;88(Suppl 1):S30–9.
   PubMed Web of Science ®Google Scholar
• Krovi SA, Johnson LM, Luecke E, et al. Advances in long-acting injectables, implants, and vaginal rings for contraception and HIV prevention. Adv Drug Deliv Rev. 2021 Sep;176:113849.
   PubMed Web of Science ®Google Scholar
• Hoesley CJ, Chen BA, Anderson PL, et al. Phase 1 safety and pharmacokinetics study of MK-2048/Vicriviroc (MK-4176)/MK-2048A Intravaginal rings. Clinl Infect Dis. 2019 Mar 19;68(7):1136–1143.
   PubMed Web of Science ®Google Scholar
• Liu AY, Zhang J, Anderson PL, et al. Phase 1 pharmacokinetic trial of 2 intravaginal rings containing different dose strengths of vicriviroc (MK-4176) and MK-2048. Clinl Infect Dis. 2019 Mar 19;68(7):1129–1135.
   PubMed Web of Science ®Google Scholar
• Devlin B, Nuttall J, Wilder S, et al. Development of dapivirine vaginal ring for HIV prevention. Antiviral Res. 2013 Dec;100(Suppl:S3–8). DOI:https://doi.org/10.1016/j.antiviral.2013.09.025
   Google Scholar
• Malcolm RK, Boyd PJ, McCoy CF, et al. Microbicide vaginal rings: technological challenges and clinical development. Adv Drug Deliv Rev. 2016 Aug 1;103:33–56.
   PubMed Web of Science ®Google Scholar
• Spence P, Nel A, van Niekerk N, et al. Post-use assay of vaginal rings (VRs) as a potential measure of clinical trial adherence. J Pharm Biomed Anal. 2016;125:94–100.
   PubMed Web of Science ®Google Scholar
• Nel A, Bekker LG, Bukusi E, et al. Safety, acceptability and adherence of dapivirine vaginal ring in a microbicide clinical trial conducted in multiple countries in Sub-Saharan Africa. PloS One. 2016;11(3):e0147743.
   PubMed Web of Science ®Google Scholar
• Nel AM, Smythe SC, Habibi S, et al. Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. Hydroxyethyl cellulose-based universal placebo gel. J Acquir Immune Defic Syndr. 2010 Oct 1;55(2):161–169.
   PubMed Web of Science ®Google Scholar
• Nel AM, Coplan P, van de Wijgert JH, et al. Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS. 2009 Jul 31;23(12):1531–1538.
   PubMed Web of Science ®Google Scholar
• Nel AM, Coplan P, Smythe SC, et al. Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-Negative women. AIDS Res Hum Retroviruses. 2010;26(11):1181–1190.
   PubMed Web of Science ®Google Scholar
• Kamali A, Byomire H, Muwonge C, et al. A randomised placebo-controlled safety and acceptability trial of PRO 2000 vaginal microbicide gel in sexually active women in Uganda. Sex Transm Infect. 2010;86(3):222–226.
   PubMed Web of Science ®Google Scholar
• Rees H, Delany-Moretlwe S, Lombard C, et al. FACTS 001 phase III trial of pericoital tenofovir 1% gel FOR HIV prevention in women. 22nd Conference on Retroviruses and Opportunistic Infections (CROI). Seattle, Washington.
   Google Scholar
• van der Straten A, Brown ER, Marrazzo JM, et al. Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study. J Int AIDS Soc. 2016;19(1):20642.
   PubMed Web of Science ®Google Scholar
• Androit MC, Colas SH;, Cray A;, et al. Silicones in industrial applications: dow corning. 2009.
   Google Scholar
• Nel A, van Niekerk N, Van Baelen B, et al. Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study. Lancet HIV. 2021 Feb;8(2):e77–e86.
   PubMed Web of Science ®Google Scholar
• Mayo AJ, Browne EN, Montgomery ET, et al. Acceptability of the dapivirine vaginal ring for HIV-1 prevention and association with adherence in a phase III trial. AIDS Behav. 2021;25(8):2430–2440.
   PubMed Web of Science ®Google Scholar
• Montgomery ET, van der Straten A, Chitukuta M, et al. Acceptability and use of a dapivirine vaginal ring in a phase III trial. AIDS. 2017;31(8):1159–1167.
   PubMed Web of Science ®Google Scholar
• Woolfson AD, Malcolm RK, Morrow RJ, et al. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Int J Pharm. 2006 Nov 15;325(1–2):82–89.
   PubMed Web of Science ®Google Scholar
• Malcolm RK, Woolfson AD, Toner CF, et al. Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. J Antimicrob Chemother. 2005;56(5):954–956.
   PubMed Web of Science ®Google Scholar
• Nel A, Smythe S, Young K, et al. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr. 2009 Aug 1;51(4):416–423.
   PubMed Web of Science ®Google Scholar
• Siepmann J, Peppas NA. Higuchi equation: derivation, applications, use and misuse. Int J Pharm. 2011 Oct 10;418(1):6–12.
   PubMed Web of Science ®Google Scholar
• Nel A, Haazen W, Nuttall J, et al. A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women. AIDS. 2014;28(10):1479–1487.
   PubMed Web of Science ®Google Scholar
• Nel A, Haazen W, Nuttall J, et al. Pharmacokinetics and safety assessment of anti-HIV dapivirine vaginal microbicide rings with multiple dosing. J AIDS Clin Res. 2014;5(355):2.
   Google Scholar
• Nel A, Haazen W, Russell M, et al. Local and systemic pharmacokinetic profile of dapivirine vaginal ring-004 when used continuously over various periods up to twelve weeks (poster 425). In: BV IPfMSLSSKP, ed. CROI 2015. Seattle, WA: International Partnership for Microbicides; SGS Life Science Services; Kinesis Pharma BV; 2015.
   Google Scholar
• Noguchi LM, Hoesley C, Kelly C, et al. Pharmacokinetics of dapivirine transfer into blood plasma, breast milk, and cervicovaginal fluid of lactating women using the dapivirine vaginal ring. Antimicrob Agents Chemother. 2019;AAC: 01930–18.
   Google Scholar
• Nel A, Haazen W, Russell M, et al. Drug-drug interactions between the dapivirine vaginal ring (ring-004) and miconazole nitrate vaginal capsule (Gyno-Daktarin®). AIDS Res Hum Retroviruses. 2014;30(S1):A144–A44.
   Web of Science ®Google Scholar
• Nel ALM, van Niekerk N, Walsh T, et al. Female condom functionality in the presence of a vaginal ring (poster 995). In: Council IPfMCFH, ed. CROI 2015. Seattle, WA: International Partnership for Micorbicides/California Family Health Council; 2015.
   Google Scholar
• Van Niekerk N, Noukens J, Nuttall J, et al. Pharmacokinetics (PK) of dapivirine vaginal ring (25 mg) co-administered with clotrimazole. AIDS Res Hum Retroviruses. 2018;34: 342–342 Supplement: 1 Meeting Abstract: P21.04.
   Web of Science ®Google Scholar
• Nel A, Smit M, Nuttall J, et al. Effect of menses and tampon use on the pharmacokinetics of dapivirine vaginal ring. 9th IAS Conference On HIV Science Paris, France; 2017 July 23-26.
   Google Scholar
• Nel A, Bekker LG, Bukusi E, et al. Safety, acceptability and adherence of dapivirine vaginal ring in a microbicide clinical trial conducted in multiple countries in Sub-Saharan Africa. PLoS One. 2016;11(3):e0147743.
   PubMed Web of Science ®Google Scholar
• Chen BA, Zhang J, Gundacker HM, et al. Phase 2a safety, pharmacokinetics, and acceptability of dapivirine vaginal rings in US postmenopausal women. Clin Infect Dis. 2019;68(7):1144–1151 .
   Web of Science ®Google Scholar
• Bunge KE, Levy L, Szydlo DW, et al. Brief report: phase iia safety study of a vaginal ring containing dapivirine in adolescent young women. J Acquir Immune Defic Syndr. 2020 Feb 1;83(2):135–139.
   PubMed Web of Science ®Google Scholar
• Nel A, van Niekerk N, Kapiga S, et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016 Dec 1;375(22):2133–2143.
   PubMed Web of Science ®Google Scholar
• Brown ER, Hendrix CW, van der Straten A, et al. Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial. J Int AIDS Soc. 2020 Nov;23(11):e25634.
   PubMed Web of Science ®Google Scholar
• Baeten JM, Palanee-Phillips T, Mgodi NM, et al. Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study. Lancet HIV. 2021 Feb;8(2):e87–e95.
   PubMed Web of Science ®Google Scholar
• Chen BA, Panther L, Marzinke MA, et al. Phase 1 safety, pharmacokinetics, and pharmacodynamics of dapivirine and maraviroc vaginal rings: a double-blind randomized trial. J Acquir Immune Defic Syndr. 2015;70(3):242–249.
   PubMed Web of Science ®Google Scholar
• Achilles S, Kelly CW, Blithe DL, et al. Safety and pharmacokinetics of dapivirine and levonorgestrel vaginal rings for multipurpose prevention of HIV and pregnancy. Madrid (Spain): HIV Research for Prevention (HIVR4P). 2018.
   Google Scholar
• Achilles S, Kelly CW, Blithe DL, et al. Pharmacokinetics, safety, and vaginal bleeding associated with continuous versus cyclic 90-day use of dapivirine and levonorgestrel vaginal rings for multipurpose prevention of HIV and pregnancy. Cape Town (South Africa) (virtual): HIV Research for Prevention (HIVR4P). 2014.
   Google Scholar
• Malcolm K, McCoy C, Murphy D, et al. Thermal properties and eutectic behaviour of dapivirine in combination with steroid hormones and other antiretrovirals. AIDS Res Hum Retroviruses. 2014;30(S1):A140–A40.
   Web of Science ®Google Scholar
• Boyd P, Fetherston SM, McCoy CF, et al. Matrix and reservoir-type multipurpose vaginal rings for controlled release of dapivirine and levonorgestrel. Int J Pharm. 2016 Sep 10;511(1):619–629.
   PubMed Web of Science ®Google Scholar
• Malcolm K, Woolfson D, Russell J, et al. Influence of silicone elastomer solubility and diffusivity on the in vitro release of drugs from intravaginal rings. J Control Release. 2003 Jun 24;90(2):217–225.
   PubMed Web of Science ®Google Scholar
• Malcolm RK, Veazey RS, Geer L, et al. Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. Antimicrob Agents Chemother. 2012 May;56(5):2251–2258.
   PubMed Web of Science ®Google Scholar
• DrugBank. Darunavir (DB01264). [ cited 2021 Oct 15]. Available from: http://www.drugbank.ca/cgi-bin/getCard.cgi?CARD=DB01264.txt
   Google Scholar
• Human Metabolome Database (HMDB). Levonorgestrel (HMDB0014511). [ cited 2021 Oct 15]. Available from: https://hmdb.ca/metabolites/HMDB0014511
   Google Scholar
• Penrose KJ, Wallis CL, Brumme CJ, et al. Frequent cross-resistance to dapivirine in HIV-1 subtype C-infected individuals on failing first-line antiretroviral therapy in South Africa. Antimicrob Agents Chemother. 2017;61(2):e01805–16.
   PubMed Web of Science ®Google Scholar
• Parikh UM, Halvas EK, Magaret CA, et al. HIV-1 resistance outcomes in seroconverters from the MTN-020/ASPIRE dapivirine vaginal ring study. New Rochelle (NY): AIDS research and human retroviruses; 2016. p. 43-43.
   Google Scholar
• Parikh U, Heaps A, Penrose K, et al. Sensitive next-generation sequencing of HIV-1 from seroconverters in the MTN-020/ASPIRE dapivirine vaginal ring study. New Rochelle (NY): AIDS Res Hum Retroviruses; 2018. p. 79-79.
   Google Scholar
• Clark JT, Clark MR, Shelke NB, et al. Engineering a segmented dual-reservoir polyurethane intravaginal ring for simultaneous prevention of HIV transmission and unwanted pregnancy. PLoS One. 2014;9(3):e88509.
   PubMed Web of Science ®Google Scholar
• Johnson TJ, Srinivasan P, Albright TH, et al. Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings. Antimicrob Agents Chemother. 2012;56(3):1291–1299.
   PubMed Web of Science ®Google Scholar
• Abdool Karim SS, Abdool Karim Q, Kharsany AB, et al. Tenofovir gel for the prevention of herpes simplex virus type 2 infection. N Engl J Med. 2015;373(6):530–539.
   PubMed Web of Science ®Google Scholar
• Marrazzo JM, Rabe L, Kelly C, et al. Tenofovir gel for prevention of herpes simplex virus type 2 acquisition: findings from the VOICE trial. J Infect Dis. 2019;219(12):1940–1947.
   PubMed Web of Science ®Google Scholar
• Reinecke I, Hofmann B, Mesic E, et al. An integrated population pharmacokinetic analysis to characterize levonorgestrel pharmacokinetics after different administration routes. J Clin Pharmacol. 2018;58(12):1639–1654.
   PubMed Web of Science ®Google Scholar
• Delany-Moretlwe S, Lombard C, Baron D, et al. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2018;18(11):1241–1250.
   PubMed Web of Science ®Google Scholar
• Koetsawang S, Gao J, Krishna U, et al. Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. I. Contraceptive efficacy and side effects. World Health Organization. Task force on long-acting systemic agents for fertility regulation. Contraception. 1990;41(2):105–124.
   PubMed Web of Science ®Google Scholar
• Elder MG, Lawson JP, Elstein M, et al. The efficacy and acceptability of a low-dose levonorgestrel intravaginal ring for contraception in a UK cohort. Contraception. 1991;43(2):129–137.
   PubMed Web of Science ®Google Scholar
• Sarkar NN. Steroidal contraceptive vaginal rings. Int J Clin Pract. 2003;57(5):392–395.
   PubMed Web of Science ®Google Scholar
• Thurman AR, Schwartz JL, Ravel J, et al. Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings. PLoS One. 2019;14(5):e0217229.
   PubMed Web of Science ®Google Scholar
• Thurman AR, Schwartz JL, Brache V, et al. Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women. PLoS One. 2018;13(6):e0199778.
   PubMed Web of Science ®Google Scholar
• Thurman A, Brache V, Ouattara A, et al. Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of a multipurpose prevention vaginal ring containing tenofovir and levonorgestrel. Cape Town (South Africa) (virtual): HIV Research for Prevention (HIVR4P)
   Google Scholar
• Mugo N, Mudhune V, Heffron R, et al. Randomized, placebo-controlled trial of safety, pharmacokinetics, and pharmacodynamics of 90-day intravaginal rings (IVRs) releasing tenofovir (TFV) with and without Levonorgestrel (LNG) among women in Western Kenya. Cape Town (South Africa) (virtual): HIV Research for Prevention (HIVR4P); 2021 Jan 27–Feb 4.
   Google Scholar
• Ju S, Ouattara A, Thurman A, et al. Anti-HIV activity and drug concentrations in tenofovir-based products: intravaginal ring versus oral tablet. Madrid Spain: HIV Research for Prevention (HIVR4P). 2018.
   Google Scholar
• Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol. 1991;29(2):297–301.
   PubMed Web of Science ®Google Scholar
• Pandya IJ, Mortimer D, Sawers RS. A standardized approach for evaluating the penetration of human spermatozoa into cervical mucus in vitro. Fertil Steril. 1986;45(3):357–365.
   PubMed Web of Science ®Google Scholar
• Nulsen J, Wheeler C, Ausmanas M, et al. Cervical mucus changes in relationship to urinary luteinizing hormone. Fertil Steril. 1987;48(5):783–786.
   PubMed Web of Science ®Google Scholar
• Leader A, Wiseman D, Taylor PJ. The prediction of ovulation: a comparison of the basal body temperature graph, cervical mucus score, and real-time pelvic ultrasonography. Fertil Steril. 1985;43(3):385–388.
   PubMed Web of Science ®Google Scholar
• Insler V, Melmed H, Eichenbrenner I, et al. The cervical score: a simple semiquantitative method for monitoring of the menstrual cycle. Int J Gynecol Obstetrics. 1972;10(6):223–227.
   Google Scholar
• Abidogun KA, Ojengbede OA, Fatukasi UI. Prediction and detection of ovulation: an evaluation of the cervical mucus score. Afr J Med Med Sci. 1993;22(1):65–69.
   PubMedGoogle Scholar
• Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354(795–802). DOI:https://doi.org/10.1016/S0140-6736(99)80008-7
   Google Scholar
• Tolley E, Hanif H, Zissette S, et al. What women want in a multipurpose vaginal ring: findings from a phase 1 trial in the U.S. and the Dominican Republic. Cape Town (South Africa) (virtual): HIV Research for Prevention (HIVR4P); 2021 Jan 27–Feb 4.
   Google Scholar
• Gautheron P, Dukic M, Alix D, et al. Bovine corneal opacity and permeability test: an in vitro assay of ocular irritancy. Fundam Appl Toxicol. 1992 Apr;18(3):442–449.
   PubMedGoogle Scholar
• Dabee S, Mugo N, Mudhune V, et al. Tenofovir-only and tenofovir/levonorgestrel intravaginal rings are unlikely to impact the genital microbiota of sub-Saharan women. Cape Town (South Africa) (virtual): HIV Research for Prevention (HIVR4P); 2021 Jan 27–Feb 4.
   Google Scholar
• Clark MR, Evanoff AJ, Anderson SM, et al. Long-acting intrauterine system delivers integrase inhibitor throughout the reproductive tract of rabbits and macaques. Chicago (IL): HIV Research for Prevention (HIVR4P); 2016 Oct 17-21.
   Google Scholar
• Thurman AR, Clark MR, Doncel GF. Multipurpose prevention technologies: biomedical tools to prevent HIV-1, HSV-2, and unintended pregnancies. Infect Dis Obstet Gynecol. 2011;2011:1–10.
   PubMedGoogle Scholar
• de Leede LGJ, Govers CPM, Denijs H. A multicompartment vaginal ring-system for independently adjustable release of contraceptive steroids. Contraception. 1986;34(6):589–602.
   PubMed Web of Science ®Google Scholar
• Duncan GW. inventor The Upjohn Company, assignee. Medicated Devices and Methods patent U.S. Patent 3,545,439. 1970 Dec 8.
   Google Scholar
• Oddsson K, Leifels-Fischer B, de Melo NR, et al. Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial. Contraception. 2005;71:176–182.
   PubMed Web of Science ®Google Scholar
• Romano J, Variano B, Coplan P, et al. Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res Hum Retroviruses. 2009;25(5):483–488.
   PubMed Web of Science ®Google Scholar
• Johnson TJ, Gupta KM, Fabian J, et al. Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir. Eur J Pharm Sci. 2010;39(4):203–212.
   PubMed Web of Science ®Google Scholar
• Singer R, Mawson P, Derby N, et al. An intravaginal ring that Releases the NNRTI MIV-150 reduces SHIV transmission in macaques. Sci Transl Med. 2012;4(150). DOI:https://doi.org/10.1126/scitranslmed.3003936
   Google Scholar
• Morrow RJ, Woolfson AD, Donnelly L, et al. Sustained release of proteins from a modified vaginal ring device. Eur J Pharm Biopharm. 2011;77(1):3–10.
   PubMed Web of Science ®Google Scholar
• Baum MM, Butkyavichene I, Gilman J, et al. An intravaginal ring for the simultaneous delivery of multiple drugs. J Pharm Sci. 2012;101(8):2833–2843.
   PubMed Web of Science ®Google Scholar
• Baum MM, Butkyavichene I, Churchman SA, et al. An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate. Int J Pharmaceutics. 2015;495(1):579–587.
   PubMed Web of Science ®Google Scholar
• Moss JA, Malone AM, Smith TJ, et al. Pharmacokinetics of a mutipurpose pod-intravaginal ring simultaneously delivering five drugs in the ovine model. Antimicrob Agents Chemother. 2013;57(8):3994–3997.
   PubMed Web of Science ®Google Scholar
• Moss J, Malone A, Smith T, et al. Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring. Antimicrob Agents Chemother. 2012;56(2):875–882.
   PubMed Web of Science ®Google Scholar
• Moss JA, Baum MM, Malone AM, et al. Tenofovir and tenofovir disoproxil fumarate pharmacokinetics from intravaginal rings. AIDS. 2012;26(6):707–710.
   PubMed Web of Science ®Google Scholar
• Moss JA, Butkyavichene I, Churchman SA, et al. Combination pod-intravaginal ring delivers antiretroviral agents for HIV prophylaxis: pharmacokinetic evaluation in an ovine model. Antimicrob Agents Chemother. 2016;60(6):3759–3766.
   PubMed Web of Science ®Google Scholar
• Moss JA, Malone AM, Smith TJ, et al. Safety and pharmacokinetics of intravaginal rings delivering tenofovir in pig-tailed macaques. Antimicrob Agents Chemother. 2012;56(11):5952.
   PubMed Web of Science ®Google Scholar
• Moss JA, Srinivasan P, Smith TJ, et al. Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model. Antimicrob Agents Chemother. 2014;58(9):5125–5135.
   PubMed Web of Science ®Google Scholar
• Smith JM, Moss JA, Srinivasan P, et al. Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: pharmacokinetic evaluation in a macaque model. PLOS ONE. 2017;12(10):e0185946.
   PubMed Web of Science ®Google Scholar
• Zhao C, Gunawardana M, Villinger F, et al. Pharmacokinetics and preliminary safety of pod-intravaginal rings delivering the monoclonal antibody VRC01-N for HIV prophylaxis in a macaque model. Antimicrob Agents Chemother. 2017;61(7):e02465–16.
   PubMed Web of Science ®Google Scholar
• Ursell LK, Gunawardana M, Chang S, et al. Comparison of the vaginal microbial communities in women with recurrent genital HSV receiving Acyclovir intravaginal rings. Antiviral Res. 2014;102:87–94.
   PubMed Web of Science ®Google Scholar
• Gunawardana M, Mullen M, Yoo J, et al. Sustained delivery of commensal bacteria from pod-intravaginal rings. Antimicrob Agents Chemother. 2014;58(4):2262–2267.
   PubMed Web of Science ®Google Scholar
• Roehr B. FDA approves first drug to prevent HIV infection. BMJ. 2012;345:e4879.
   PubMed Web of Science ®Google Scholar
• Srinivasan P, Moss JA, Gunawardana M, et al. Topical delivery of tenofovir disoproxil fumarate and emtricitabine from pod-intravaginal rings protects macaques from multiple SHIV exposures. PLOS ONE. 2016;11(6):e0157061.
   PubMed Web of Science ®Google Scholar
• Keller M, Malone A, Carpenter C, et al. Safety and pharmacokinetics of acyclovir in women following release from a silicone elastomer vaginal ring. J Antimicrob Chemother. 2012;67(8):2005–2012.
   PubMed Web of Science ®Google Scholar
• Vincent KL, Moss JA, Marzinke MA, et al. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: a Phase I trial. PLoS Med. 2018;15(9):e1002655.
   PubMed Web of Science ®Google Scholar
• Vincent KL, Moss JA, Marzinke MA, et al. Phase I trial of pod-intravaginal rings delivering antiretroviral agents for HIV-1 prevention: rectal drug exposure from vaginal dosing with tenofovir disoproxil fumarate, emtricitabine, and maraviroc. PLOS ONE. 2018;13(8):e0201952.
   PubMed Web of Science ®Google Scholar
• Palanee-Phillips T, Roberts S, Montgomery E, et al. Frequency of partner-related social harms and their impact on adherence to the dapivirine vaginal ring during the MTN020/aspire HIV prevention trial. New Rochelle (NY): AIDS research and human retroviruses; 2016. p. 94-94.
   Google Scholar
• Roberts ST, Nair G, Baeten JM, et al. Impact of male partner involvement on women’s adherence to the dapivirine vaginal ring during a phase III HIV prevention trial. AIDS Behav. 2020;24(5):1432–1442.
   Web of Science ®Google Scholar
• Montgomery ET, Beksinska M, Mgodi N, et al. End-user preference for and choice of four vaginally delivered HIV prevention methods among young women in South Africa and Zimbabwe: the Quatro Clinical Crossover Study. J Int AIDS Soc. 2019 May;22(5):e25283.
   PubMed Web of Science ®Google Scholar
• Musara P, Milford C, Shapley-Quinn MK, et al. Preferences and acceptability of vaginal delivery forms for HIV prevention among women, male partners and key informants in South Africa and Zimbabwe: qualitative findings. AIDS Behav. 2021;25(1):124–138.
   PubMed Web of Science ®Google Scholar
• Weinrib R, Browne EN, Shapley-Quinn MK, et al. Perspectives from young South African and Zimbabwean women on attributes of four (Placebo) vaginal microbicide delivery forms. AIDS Behav. 2020 Feb;24(2):637–647.
   PubMed Web of Science ®Google Scholar
• Browne EN, Montgomery ET, Mansfield C, et al. Efficacy is not everything: eliciting women’s preferences for a vaginal HIV prevention product using a discrete-choice experiment. AIDS Behav. 2020;24(5):1443–1451.
   PubMed Web of Science ®Google Scholar
• Gill K, Happel AU, Pidwell T, et al. An open-label, randomized crossover study to evaluate the acceptability and preference for contraceptive options in female adolescents, 15 to 19 years of age in Cape Town, as a proxy for HIV prevention methods (UChoose). J Int AIDS Soc. 2020 Oct;23(10):e25626.
   PubMed Web of Science ®Google Scholar
• Undie CC, RamaRao S, Mbow FB. Choosing and using the progesterone vaginal ring: women’s lived experiences in three African cities. Patient Prefer Adherence. 2020;14:1761–1770.
   PubMed Web of Science ®Google Scholar
• van der Straten A, Agot K, Ahmed K, et al. The tablets, ring, injections as options (TRIO) study: what young African women chose and used for future HIV and pregnancy prevention. J Int AIDS Soc. 2018 Mar;21(3):e25094.
   PubMed Web of Science ®Google Scholar
• Welsh NR, Malcolm RK, Devlin B, et al. Dapivirine-releasing vaginal rings produced by plastic freeforming additive manufacturing. Int J Pharmaceutics. 2019;572:118725.
   PubMed Web of Science ®Google Scholar
• Tiboni M, Campana R, Frangipani E, et al. 3D printed clotrimazole intravaginal ring for the treatment of recurrent vaginal candidiasis. Int J Pharm. 2021;596:120290.
   PubMed Web of Science ®Google Scholar
• Fu J, Yu X, Jin Y. 3D printing of vaginal rings with personalized shapes for controlled release of progesterone. Int J Pharm. 2018;539(1–2):75–82.
   PubMed Web of Science ®Google Scholar
• Janusziewicz R, Mecham SJ, Olson KR, et al. Design and characterization of a novel series of geometrically complex intravaginal rings with digital light synthesis. Adv Mater Technol. 2020;5(8):2000261.
   PubMed Web of Science ®Google Scholar
• Taha TE, Hoover DR, Dallabetta GA, et al. Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. AIDS. 1998;12(13):1699–1706.
   PubMed Web of Science ®Google Scholar